Pular para o conteúdo principal
Início

Dedicated to discovery

  • Sobre a ELGA
    • Sobre a ELGA
    • Carreiras
    • Eventos
  • Apoio
    • Planeamento laboratorial
  • Contacto
  • EN
  • DE
  • ES
  • FR
  • IT
  • EN-US
Início
  • Produtos
    • PURELAB
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® Chorus 2 +
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY® 30
    • Gama completa dos produtos ELGA
  • Aplicações
    • Análise microbiológica
    • Bioquímica Clínica
    • Cromatografia gasosa
    • Cromatografia líquida
      • High Performance Liquid Chromatography
    • Culturas de célula
    • Eletroquímica
    • Espectrofotometria
    • Espectrometria de massa
    • Espectroscopia Atómica
    • Genética
    • High Performance Liquid Chromatography (HPLC)
    • Imunoquímica
    • Requisitos de água para laboratório em geral
  • Tecnologias
    • Carbono ativado
    • Eletrodeionização (EDI)
    • Filtração
    • Osmose Reversa
    • PureSure
    • Troca iónica
    • Ultravioleta
  • Impurezas na água
    • Compostos biológicos
    • Compostos inorgânicos
    • Gases dissolvidos
    • Microrganismos e bactérias
    • Partículas
  • Conhecimento
    • BROSCHÜREN
    • Blogue
    • Estudos de caso
    • Água ultrapura
    • Guias e Livros brancos
  • Where to buy
  • Contacto
Home
  • Contacto
  • Produtos
    • PURELAB
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® Chorus 2 +
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY® 30
    • Gama completa dos produtos ELGA
  • Aplicações
    • Análise microbiológica
    • Bioquímica Clínica
    • Cromatografia gasosa
    • Cromatografia líquida
      • High Performance Liquid Chromatography
    • Culturas de célula
    • Eletroquímica
    • Espectrofotometria
    • Espectrometria de massa
    • Espectroscopia Atómica
    • Genética
    • High Performance Liquid Chromatography (HPLC)
    • Imunoquímica
    • Requisitos de água para laboratório em geral
  • Tecnologias
    • Carbono ativado
    • Eletrodeionização (EDI)
    • Filtração
    • Osmose Reversa
    • PureSure
    • Troca iónica
    • Ultravioleta
  • Impurezas na água
    • Compostos biológicos
    • Compostos inorgânicos
    • Gases dissolvidos
    • Microrganismos e bactérias
    • Partículas
  • Conhecimento
    • BROSCHÜREN
    • Blogue
    • Estudos de caso
    • Água ultrapura
    • Guias e Livros brancos
  • Where to buy
  • Contacto
  • Sobre a ELGA
    • Sobre a ELGA
    • Carreiras
    • Eventos
  • Apoio
    • Planeamento laboratorial
  • Contacto
  • EN
  • DE
  • ES
  • FR
  • IT
  • EN-US
  • Política de privacidade
  • Termos e condições
  • Conformidade legal global
  • Patentes
  • Trademarks
  • Impressum
  • Targeting Drug Delivery to the Brain Using Inhaled Microparticle Agglomerates
Clinical & Pharma
Cool Science

Targeting Drug Delivery to the Brain Using Inhaled Microparticle Agglomerates

28 fev 2020
- by Dr Alison Halliday

Doctor checking brain testing result with computer interface, innovative technology in science and medicine concept

Ultrapure water is a key reagent in a new study showing that a new inhaled powder formulation may be an effective way to deliver an anti-viral drug to the brain, offering a new approach for treating central nervous system (CNS) infections.

With people traveling much more frequently, living in more densely populated areas, and coming into closer contact with wild animals, the potential for emerging infectious diseases to spread rapidly and cause global epidemics is a major concern.Many emerging viral infections, such as the West Nile virus, involve the central nervous system (CNS) causing life-threatening complications including encephalitis or meningitis. Others, including the measles virus, can cause CNS complications soon after infection, or a few years later due to viral persistence.

But treating viral infections in the CNS is challenging, due to the difficulties of delivering antiviral drugs across the blood-brain-barrier (BBB). Delivering drugs through the nasal passages offers an attractive option as it exploits an entry route directly into the CNS, bypassing the BBB. The antiviral drug ribavirin (RBV) has potential uses for treating infections both in humans and animals.

Nose-to-brain anti-viral drug delivery

A team of Italian researchers previously showed that RBV can reach the brain by nasal administration using an aqueous solution. But there are potential advantages to developing a powdered form including improved chemical stability, increased deliverable doses, longer residence time and contact with the nasal mucosa.

Now the results from a new study published in Drug Delivery, show that a new powder formulation can improve the nose-to-brain delivery of RBV. (1) For a powder formulation to be effective, the particles need to be sufficiently large to deposit efficiently in the nasal cavity, but at the same time display a high surface area for fast dissolution. Excipients that can enhance adhesion to the mucosal surfaces or drug permeation may also be helpful.

With these properties in mind, the team chose to use particle engineering to create a powder formulation in the form of agglomerates, which they made from combining micro-ionized RBV with spray-dried microparticles containing one of three different potentially absorption-enhancing excipients - mannitol, chitosan or α-cyclodextrin.

Ultrapure water is a key reagent

The researchers used degassed, ultrapure water from a PURELAB® Flex water purification system by ELGA LabWater across all of their experiments - reducing the risk of introducing contaminants that may affect their results.

The researchers quantified RBV concentrations in their samples using either a reverse-phase high-performance liquid chromatography (HPLC) or a liquid chromatography-mass spectrometry (LC-MS) method. They also characterized their size distribution, morphology and technological properties of their different particles using a variety of techniques. 

Encouraging results for targeted brain delivery

They found that their microparticle agglomerates containing α-cyclodextrin/lecithin outperformed the other formulations for drug permeation across nasal tissues, demonstrating this formulation gives an overall higher accumulation of RBV in brain compartments compared to the highly soluble micronized powder.

The nasal administration route may also have the added advantage of reducing systemic side effects, identifying significantly higher olfactory bulb to plasma ratios to that of the same dose of RBV administered intravenously by comparing their results with those from their previous experiments. 

This exciting new technological approach of agglomerating excipient microparticles combined with the raw drug material has the potential to be a new way for nose-to-brain delivery of hydrophilic small molecules, as well as peptides or proteins.

Why choose ELGA LabWater's Purification Systems?

We are the LabWater Specialists, for over 80 years we have been working with scientists to guarantee pure and ultrapure water for their experiments and lab work. Laboratories around the world trust our water purification systems to help their researchers to achieve accurate, reliable results.


References

(1)   Giuliani et al. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Delivery (2018), Vol 25, No 1, p376-387. 


Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

 

  • Sales Enquiry
  • Obter uma cotação
  • Technical Support
  • Encontre um parceiro aprovado

Sales Enquiry

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

Obter uma cotação

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

Technical Support

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

Sede da ELGA LabWater

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
Reino Unido
T: +44 (0) 203 567 7300
F: +44 (0) 203 567 7205

Estudos de caso

  • Abbott Diagnostics
  • DASA Medical Diagnostics
  • NeoDIN Medical Institute
  • North Staffordshire NHS Trust
  • Olsberg Vocational College

Recursos

  • Saber mais sobre água ultrapura
  • Guias e Livros Brancos
  • Tecnologias de purificação
  • Aplicações
  • Impurezas na água
  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?

© VWS (UK) Ltd. negociando como ELGA LabWater.2025-Todos os direitos reservados.
ELGA é a marca global de água para laboratórios da Veolia.

  • Política de privacidade
  • Termos e condições
  • Conformidade legal global
  • Patentes
  • Trademarks
  • Impressum
  • Idioma
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Outros sítios Web da Veolia
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies
Elga Veolia
TOP

© 2017 ELGA Veolia